Abstract
KN024 showed pembrolizumab improved survival compared to platinum doublet chemotherapy (PDC) in 1st-line setting for advanced NSCLC with PDL1≥50%. KN189/KN407 demonstrated pembrolizumab/PDC in advanced NSCLC achieved superior 12-month survival compared with PDC. In patients with PDL1≥50% cross 3 trials, objective response rate with pembrolizumab in KN024 was 45% compared to 60% with pembrolizumab/PDP in KN189/407. The clinical question is: can we distinguish this 45% of patients who are best treated with pembrolizumab alone, and who need additional PDC? Currently, there are no biomarkers or clinicopathological features to distinguish this population.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
